Maria Serena Benassi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Serena Benassi has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
- Laura Pazzaglia
Laboratory of Oncology Research and Functional Genomics (ONCOGEN), IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
53 shared publications - Katia Scotlandi
Laboratory of Oncology Research and Functional Genomics (ONCOGEN), IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
47 shared publications - Angela Di Giannatale
Hematology/Oncology and Cell and Gene Therapy Unit, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
46 shared publications - Carmen Blanco-Aparicio
Experimental Therapeutics Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain
46 shared publications - Charles P. Theuer
TRACON Pharmaceuticals, Inc., San Diego, CA
46 shared publications - Claudia Savini
Microenvironment and Metastasis Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
46 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 1 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Analysis of ENG expression and plasma circulating sEVs in human PNSTs.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 1 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Analysis of ENG expression and plasma circulating sEVs in human PNSTs.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 2 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
ENG knockdown leads to downregulation of pro-angiogenic and pro-metastatic gene signatures in MPNST cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 2 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
ENG knockdown leads to downregulation of pro-angiogenic and pro-metastatic gene signatures in MPNST cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 3 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
ENG knockdown does not affect MPNST cell apoptosis in vivo.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 3 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
ENG knockdown does not affect MPNST cell apoptosis in vivo.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Significant deregulated genes in shENG versus shScramble STS26T cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Significant deregulated genes in shENG versus shScramble STS26T cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 5 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Combined anti-ENG/anti-MEK therapy inhibits MPNST growth without toxicity in vivo.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 5 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Combined anti-ENG/anti-MEK therapy inhibits MPNST growth without toxicity in vivo.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 3 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Dual inhibition of ENG and MEK efficiently blocks ENG-Smad1/5 and MAPK/ERK pathway activation in ST88-14 cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 3 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Dual inhibition of ENG and MEK efficiently blocks ENG-Smad1/5 and MAPK/ERK pathway activation in ST88-14 cells.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Taqman probes used for quantitative PCR.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Taqman probes used for quantitative PCR.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 4 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Anti-ENG therapy is active against MPNST xenografts.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 4 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Anti-ENG therapy is active against MPNST xenografts.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 6 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Dual inhibition of ENG and MEK efficiently blocks ENG-Smad1/5 and MAPK/ERK pathway activation in ST88-14 cells.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 6 from Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis
Dual inhibition of ENG and MEK efficiently blocks ENG-Smad1/5 and MAPK/ERK pathway activation in ST88-14 cells.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 6 from Endoglin, a novel biomarker and therapeutical target to prevent malignant peripheral nerve sheath tumor growth and metastasis
Dual inhibition of ENG and MEK efficiently blocks ENG-Smad1/5 and MAPK/ERK pathway activation in ST88-14 cells.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 6 from Endoglin, a novel biomarker and therapeutical target to prevent malignant peripheral nerve sheath tumor growth and metastasis
Dual inhibition of ENG and MEK efficiently blocks ENG-Smad1/5 and MAPK/ERK pathway activation in ST88-14 cells.